Skip to main content
SpringerLink
Log in

Advances in the Management of Pancreatic Cancer

  • Conference paper
Progress in Anti-Cancer Chemotherapy

Part of the book series: Progress in Anti-Cancer Chemotherapy ((ANTI-CANCER,volume 3))

  • 58 Accesses

Abstract

Adenocarcinoma of the exocrine pancreas remains a profound therapeutic challenge. Incremental improvements in overall survival have been small and the current 5 year survival of patients with pancreatic cancer is only 4% [1]. In the United States, this disease is a the fourth leading cause of cancer death in men and the fifth cause of cancer death in women.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Landis SH, Murray T, Bolden S, Bolden S, Wingo PA (1998) Cancer Statistics CA Can J Clinicians 48:6–29

    Article  CAS  Google Scholar 

  2. Warshaw AL, Fernandez-del C (1992) Pancreatic caminoma. N Engl J Med 326:455–465

    Article  PubMed  CAS  Google Scholar 

  3. Crist DW, Cameron JL (1994) The current status of the Whipple operation for periampullary carcinoma. Adv Surg 25:21–49

    Google Scholar 

  4. Trede M, Schwall G, Saeger HD (1990) Survival after pancreatoduodenectomy. Ann Surg 211:447–58

    Article  PubMed  CAS  Google Scholar 

  5. Kaiser MH, Ellenberg SS (1985) Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903

    Article  Google Scholar 

  6. Gastrointestinal Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006–2010

    Article  Google Scholar 

  7. ECC09 (1997) The European Cancer Conference (Hamburg, 14–18 September) Abstracts, Eur J Cancer 33(Suppl 8): 1–380

    Google Scholar 

  8. Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, Buttmann MC, Litwin S, Salazar H, Eisenberg BL (1995) A pilot study of preoperative chemoradi- ation for patients with localized adenocarcinoma of the pancreas. Am J Surg 169:71–77

    Article  PubMed  CAS  Google Scholar 

  9. Evans EB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, Chamsangavej C, Fenogllo CH, Amers FC (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335–1339

    Article  PubMed  CAS  Google Scholar 

  10. Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goxwitz MS, Rich TA, Evans DB (1997) Preoperative and postoperative chemoradiation strategies in patients with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928–937

    PubMed  CAS  Google Scholar 

  11. Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kaiser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48:1705–1710

    Article  PubMed  CAS  Google Scholar 

  12. Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80:751–755

    Article  Google Scholar 

  13. Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, Nagahama H, Sumi M, Kagami Y, Ikeda H (1997) Protracted 5-Fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 79:1516–1520

    Article  PubMed  CAS  Google Scholar 

  14. Robertson JM, Ensminger WD, Walker S, Lawrence TS (1997) A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 37:331–335

    Article  PubMed  CAS  Google Scholar 

  15. Safran H, King TP, Choy H, Hesketh PH, Wolfe B, Altenhein E, Sikov W, Rosmarin A, Akerly W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ (1997) Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study. J Clin Oncol 153:901–907

    Google Scholar 

  16. Boz G, DePaoli A, Roncadin M, Franchin G, Galligioni E, Arcicasa M, Bortolus R, Gobitti C, Minatel E, Innocente R et al (1991) Radiation therapy combined with chemotherapy for inoperable pancreatic carcinoma. Tumori 77:61–64

    PubMed  CAS  Google Scholar 

  17. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensiti- zation of pancreatic cancer cells by 2’, 2’-difluoro-2’-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867–872

    Article  PubMed  CAS  Google Scholar 

  18. Roldan GE, Gunderson LL, Nagomey DM, Martin JK, Ilstmp DM, Holbrook MA, Kvols LK, Mcllrath DC (1988) External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61:1110–1116

    Article  PubMed  CAS  Google Scholar 

  19. Tempero M (1998) Chemotherapy of Pancreatic Cancer. In: Reber H(ed) Pancreatic Cancer: Pathogenesis, Diagnosis, and Treatment Humana Press, Totowa, NJ pp 265- 280

    Google Scholar 

  20. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo JH (1996) A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78:627–632

    PubMed  CAS  Google Scholar 

  21. Ahlgren JD (1996) Chemotherapy for pancreatic carcinoma. Cancer 78:654–663

    PubMed  CAS  Google Scholar 

  22. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2,2’-difluorodeoxycy- tidine) in patients with adenocarcinoma of the pancreas. Invest New Crugs 12:29–34

    Article  CAS  Google Scholar 

  23. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Gripps MC, Portenoy RK, Stomiolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  24. Wong A, Chan A, Arthur K (1987) Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 71:749–750

    PubMed  CAS  Google Scholar 

  25. Keating JJ, Johnson PJ, Cochrane AMG, Gazzard BG, Krasner N, Smith PM, Trewby PN, Wheeler P, Wilkinson SP, Williams R (1989) A prospective randomised trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 60:789–792

    Article  PubMed  CAS  Google Scholar 

  26. Allegretti A, Lionetto R, Saccomanno S, Paganuzzi M, Onetto M, Martinoli C, Rollandi G, Marugo M, Fazzuoli L, Pugliese V (1993) LH-RH analogue treatment in adenocarcinoma of the pancreas: A phase II study. Oncology 50:77–80

    Article  PubMed  CAS  Google Scholar 

  27. Philip PA, Carmichael J, Tonkin K, Buamah PK, Britton J, Dowsett M, Harris AL (1993) Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 67:379–382

    Article  PubMed  CAS  Google Scholar 

  28. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG (1991) Fluorouracil and high-dose leu- coverin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 9:2128–2133

    PubMed  CAS  Google Scholar 

  29. Scheithauer W, Pfeffel F, Komek G, Marczell A, Wiltschke C, Funovics J (1992) A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 70:1864–1866

    Article  PubMed  CAS  Google Scholar 

  30. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B (1992) Phase II evaluation of fluorouracil and recombinant ot- 2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 70:2073–2076

    Article  PubMed  CAS  Google Scholar 

  31. Smith FP, Hoth DF, Levin B, Karlin DA, Macdonald JS, Woolley PV, Schien PS (1980) 5-fluorouracil, adriamycin and mitomycin-C(FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014–2018

    Article  PubMed  CAS  Google Scholar 

  32. Bukowski RM, Schacter LP, Groppe CW, Hewlett JS, Weick JK, Livingston RB (1982) Phase II trial of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 50:197–200

    Article  PubMed  CAS  Google Scholar 

  33. Gastrointenstinal Tumor Study Group (1986) Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomoycin C plus fluorouracil. J Clin Oncol 4:1794–1798

    Google Scholar 

  34. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R (1991) A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine and arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68:965–969

    Article  PubMed  CAS  Google Scholar 

  35. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifie DM, Barlow JF (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253:2061–2067

    Article  PubMed  CAS  Google Scholar 

  36. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard CF (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. BR J Surg 81:882–885

    Article  PubMed  CAS  Google Scholar 

  37. Glimelius B, Hoffman K, Sjöden PO, Jacobsson G, Sellström H, Enander LK, Linne T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600

    Article  PubMed  CAS  Google Scholar 

  38. Mallinson CN, Rake MO, Cocking JD (1980) Chemotherapy in pancreatic cancer. Br Med J 281:1589–1591

    Article  PubMed  CAS  Google Scholar 

  39. Plunkett W, Huang P, Searcy CE et al (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 10:3–15

    Google Scholar 

  40. Brand R, Capadano M, Tempero M (1997) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15:331–341

    Article  PubMed  CAS  Google Scholar 

  41. Kawai Y, Yang LY, Plunkett W (1998) Inhibition of repair of cisplatin-induced DNA damage in human colon carcinoma cells by gemcitabine. AACR Proc 39:156, Abst #1068

    Google Scholar 

  42. Ura H, Obara T, Shudo R, Itoh A, Tanno S, Fujii T, Nishino N, Kohgo Y (1998) Selective cytotoxicity of famesylamine to pancreatic carcinoma cells and Ki-ras-trans- formed fibroblasts. Mol Carcinog 21:93–99

    Article  CAS  Google Scholar 

  43. Moasser MM, Sepp-Lorenziono L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N (1998) Famesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sei USA 95:1369–1374

    Article  CAS  Google Scholar 

  44. Aoli K, Yoshida T, Sugimura T et al (1995) Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55:3810–3816

    Google Scholar 

  45. Cai DW, Mukhopadhyay T, Roth JA (1995) Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer Gene Ther 2:199–205

    PubMed  CAS  Google Scholar 

  46. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373–376

    Article  PubMed  CAS  Google Scholar 

  47. MacLean GD, Reddish MA, Koganty RR, Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic Stn vaccine. J Immunother Emphasis Tumor Immunol 19:59–68

    Article  PubMed  CAS  Google Scholar 

  48. Jaffee EM, Pardoll DM (1997) Considerations for the clinical development of cytokine gene-transducted tumor cell vaccines. Methods 12:143–153

    Article  PubMed  CAS  Google Scholar 

  49. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD (1990) Phase II trial of interferon gamma and monoclonal antibody 17–1A in pancreatic cancer: Biologic and clinical effects. J Clin Oncol 12:2019–2026

    Google Scholar 

  50. Reithmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, and the German Cancer Aid 17–1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’C colorectal carcinoma. Lancet 343:1177–1183

    Article  Google Scholar 

  51. Tempero MA, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Wise-carver J, Colcher D (1997) High dose therapy with labeled monoclonal antibody CC49: A phase I trial. J Clin Oncol 15:1518–1528

    PubMed  CAS  Google Scholar 

  52. Leichner PK, Akabani G, Colcher D, Harrison K, Hawkins W, Eckblade M, Bara-nowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero M (1997) Patient-specific dosimetry of indium-III-and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 38:512–516

    PubMed  CAS  Google Scholar 

  53. Breitz HB, Weiden PL, Vanderheyden JL et al (1992) Clinical experience with Rhenium 186 labeled monoclonal antibodies for radioimmunotherapy: Results of Phase 1 trials. J Nucl Med 33:1099–1109

    PubMed  CAS  Google Scholar 

  54. Bramhall S (1997) The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatology 2:1–12

    Google Scholar 

Download references

Authors
  1. M. Tempero
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. MD Anderson Cencer Center, Cepartment of Breast Medical Oncology, University of Texas, 1515 Holcombe Boulevard, 77030, Houston, Texas, USA

    Gabriel N. Hortobagyi

  2. Pitié-Salpétrière Hospital, SOMPS, 47, bd de l’Hôpital, 75651, Paris Cedex 13, France

    David Khayat

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag France

About this paper

Cite this paper

Tempero, M. (1999). Advances in the Management of Pancreatic Cancer. In: Hortobagyi, G.N., Khayat, D. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 3. Springer, Paris. https://doi.org/10.1007/978-2-8178-0918-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0918-2_17

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-59666-7

  • Online ISBN: 978-2-8178-0918-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation